Heart Rhythm O2 (Dec 2021)

Atrial fibrillation in cardiac resynchronization therapy

  • Mark K. Elliott, MBBS,
  • Vishal S. Mehta, MBBS,
  • Dejana Martic, BSc (Hons),
  • Baldeep S. Sidhu, BM, PhD,
  • Steven Niederer, PhD,
  • Christopher A. Rinaldi, MD, FHRS

Journal volume & issue
Vol. 2, no. 6
pp. 784 – 795

Abstract

Read online

Patients with atrial fibrillation (AF) were largely excluded from the major clinical trials of cardiac resynchronization therapy (CRT), despite the presence of AF in up to 40% of patients receiving CRT in clinical practice. AF appears to attenuate the response to CRT, by the combination of a reduction in biventricular pacing and the loss of atrioventricular synchrony. In addition, remodeling secondary to CRT may influence the progression of AF. Management options for patients with AF and CRT include rate control, with drugs or atrioventricular node ablation, or rhythm control, with electrical cardioversion and antiarrhythmic therapy, or AF catheter ablation. The evidence for these therapies in patients with CRT is largely limited to observational studies or inferred from randomized studies in the general heart failure population. In this review, we explore the complex interaction between AF, heart failure, and CRT and discuss the evidence for the treatment options in this difficult patient cohort.

Keywords